SCHEMBL6717632

SCHEMBL6717632

Cc1cccc(C)c1NC(=O)C(c1ccccc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.47
HSP90AA1 P07900 1/20 0.47
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 6/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
THRB P10828 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
HTT P42858 2/20 0.42
POLB P06746 1/20 0.41
GAA P10253 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CXCL8 P10145 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714547 0.91 ALDH1A1 (0.46) ATMHSP90AA1CYP3A4CYP2C19ALDH1A1
SCHEMBL6717585 0.90 TP53 (0.46) LMNAMEN1KMT2A
SCHEMBL6716842 0.88 CYP1A2 (0.48) CYP3A4CYP2C19ALDH1A1LMNASMN1; SMN2
SCHEMBL6716835 0.88 CYP1A2 (0.48) CYP3A4CYP2C19ALDH1A1LMNASMN1; SMN2
SCHEMBL6719501 0.87 MAPT (0.46) CYP3A4CYP2C19ALDH1A1LMNAMEN1
SCHEMBL6716823 0.85 KCNJ11 (0.40) CYP3A4CYP2C19ALDH1A1LMNASMN1; SMN2
SCHEMBL6723623 0.83 POLB (0.51) ATMHSP90AA1ALDH1A1LMNAMEN1
SCHEMBL6716854 0.81 ALDH1A1 (0.53) HSP90AA1ALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL6715700 0.81 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL6715762 0.81 BRD4 (0.54) ALDH1A1LMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ATM 3390/4885HSP90AA1 1837/4885CYP3A4 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.